Here’s what you should know:
1. BT-11 is an orally-active, gut-restricted therapeutic. Researchers conducted a randomized, double-blind trial of 70 patients to assess the drug’s safety.
2. The drug was well-tolerated in all 70 patients, with no dose-limiting toxicities.
3. Adverse events in the BT group were like that of the placebo group.
4. Researchers tested BT-11 doses between 7 mg/kg and 100 mg/kg. They did not reach a maximum tolerated dose.
5. Landos Chairman and CEO Josep Bassaganya-Riera, PhD, said, “The results of our Phase 1 study provide the first-in-human clinical data in support of BT-11 as a novel oral treatment for IBD. We are pleased to see that BT-11 was well-tolerated and safe in healthy volunteers.”
6. Landos will begin a phase 2 study in 2019.
More articles on gastroenterology:
The PE arms race — From the deal heard round the world to what’s next in GI
The strategy behind Pardee UNC’s $16M ASC
ASC supply chain tip of the day: Find an accountability structure
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
